Table 1

Patients’ characteristics and IMVD determined with an anti-CD34 or an anti-CD105 antibody

No. of patients (%)IMVD
CD34 (mean ±SE)PCD105 (mean±SE)P
Total236 (100)179.7 ± 6.441.6 ± 3.2
Age (mean± SD, years)62.4 ± 9.7
 Lower age (<64 years)118 (50.0)181.0 ± 9.40.86942.2 ± 4.50.844
 Higher age (≥64 years)118 (50.0)178.5 ± 8.841.1 ± 4.5
Sex
 Male170 (72.0)175.4 ± 7.60.27344.1 ± 4.00.167
 Female66 (28.0)190.8 ± 11.735.3 ± 5.0
PS
 0206 (87.3)181.9 ± 6.940.6 ± 3.3
 128 (11.9)158.5 ± 18.00.60051.1 ± 12.10.562
 22 (0.8)255.5 ± 63.515.0 ± 14.0
Histologic type
 Sq85 (36.0)171.8 ± 10.70.292 (Sq vs. Ad)52.2 ± 5.90.046 (Sq vs. Ad)
 Ad130 (55.1)186.3 ± 8.50.557 (Sq vs. La)38.0 ± 3.80.215 (Sq vs. La)
 La13 (5.5)187.7 ± 26.40.960 (Ad vs. La)29.0 ± 16.90.614 (Ad vs. La)
 Others8 (3.4)
Tumor cell differentiationa
 Well differentiated80 (35.1)190.6 ± 12.237.5 ± 4.9
 Moderately differentiated90 (39.5)165.7 ± 9.00.75443.5 ± 5.00.205
 Poorly differentiated58 (25.4)188.6 ± 12.648.1 ± 7.7
p-stage
 I138 (58.5)189.9 ± 8.642.6 ± 4.2
 II44 (18.6)145.8 ± 13.20.28847.4 ± 7.10.927
 IIIa54 (22.9)181.3 ± 13.245.2 ± 6.6
  • a Other histologic types were excluded in the analysis.